Skip to main content

The Globe and Mail

Merck tops view, newer drugs cushion asthma drug blow

A sample of the drug Singulair made by Merk & Co. Inc. is seen in New York March 9, 2009.

Chip East/REUTERS

Merck & Co Inc. reported a higher-than-expected third-quarter profit, as a favorable tax rate and lower merger costs helped offset plunging sales of its former flagship product, Singulair, an asthma drug that began facing cheaper generics in August.

But overall company sales came in slightly below Wall Street expectations, as Singulair's decline outpaced already grim predictions for it.

Merck, the No. 2 U.S. drugmaker, said on Friday it earned $1.73-billion (U.S.), or 56 cents per share, compared with $1.69-billion, or 55 cents per share, a year earlier.

Story continues below advertisement

Excluding special items, Merck earned 95 cents per share. Analysts, on average, expected 92 cents.

The better-than-expected profit was largely due to the favorable impact of an overseas tax settlement as well as realization of foreign tax benefits, Merck said.

Jefferies & Co analyst Jeffrey Holford had predicted a tax rate of 26 per cent, but it came in at 20.3 per cent. He called the profit beat "low quality" because it was mostly due to the one-time tax gains.

"Gross margins were also weaker than expected," Holford said, and noted that Singulair sales were about $75-million below what he had expected.

Merck spokesman Ron Rogers said the tax gains are not expected to carry over into the fourth quarter and that the drugmaker continues to expect a full-year tax rate of about 25 per cent.

Global company revenue fell 4 per cent to $11.49-billion in the quarter, below Wall Street expectations of $11.57-billion.

Merck tightened its full-year profit forecast to between $3.78 and $3.82 per share, from its earlier view of $3.75 to $3.85 per share.

Story continues below advertisement

Sales of Singulair tumbled 55 per cent to $602-million. But a number of its newer products – including treatments for diabetes, hepatitis C and HIV – generated double-digit sales gains that helped cushion Singulair's free fall.

And revenue from Gardasil, the company's vaccine against cervical cancer, jumped 31 per cent to $581-million.

But Merck will need to launch new drugs to withstand looming generic competition for other important medicines. Its Maxalt migraine drug, with $600-million in annual sales, goes generic in December, followed next year by its Temodar brain cancer medicine, which has near-blockbuster sales of $900-million.

Over the next 18 months, the company aims to seek six drug approvals, including marketing applications for new types of therapies for insomnia and osteoporosis

Report an error
Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.